Table 2.
Treatment class combinations received by patients with HF, stratified by HF phenotype and New York Heart Association functional class
| Treatment class combination | Overall (N=1,498) | HFrEF (<50%) (n=677) | HFpEF (≥50%) (n=621) | HFrEF New York Heart Association class I (n=145) | HFrEF New York Heart Association class II–IV (n=530) |
|---|---|---|---|---|---|
| ACEi/ARB monotherapy (±othersa) | 259 (17) | 150 (22) | 60 (10) | 46 (32) | 103 (19) |
| BB monotherapy (±othersa) | 57 (4) | 18 (3) | 33 (5) | 4 (3) | 14 (3) |
| MRA monotherapy (±othersa) | 6 (0) | 3 (0) | 3 (0) | 0 (0) | 3 (2) |
| ACEi+ARB±othersa | 132 (9) | 89 (13) | 20 (3) | 38 (26) | 51 (10) |
| ACEi/ARB+BB (no MRA) ±othersa | 761 (51) | 304 (45) | 370 (60) | 74 (51) | 229 (43) |
| ACEi/ARB+MRA (no BB) ±othersa | 113 (8) | 50 (7) | 28 (5) | 6 (4) | 44 (8) |
| ACEi/ARB+BB+MRA±others | 277 (18) | 143 (21) | 113 (18) | 14 (10) | 129 (28) |
Notes: Values presented are n (%), unless otherwise stated; percentages are calculated following the exclusion of missing data and are subject to rounding. Treatment groups are not mutually exclusive. Data were obtained from patient record forms.
a
Includes therapy unrelated to treating HF and excludes other HF treatments.
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, β-blocker; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; MRA, mineralocorticoid receptor antagonist.